403 related articles for article (PubMed ID: 8725190)
1. The relaxivity of Gd-EOB-DTPA and Gd-DTPA in liver and kidney of the Wistar rat.
Shuter B; Tofts PS; Wang SC; Pope JM
Magn Reson Imaging; 1996; 14(3):243-53. PubMed ID: 8725190
[TBL] [Abstract][Full Text] [Related]
2. Relaxivity of Gd-EOB-DTPA in the normal and biliary obstructed guinea pig.
Shuter B; Wang SC; Roche J; Briggs G; Pope JM
J Magn Reson Imaging; 1998; 8(4):853-61. PubMed ID: 9702887
[TBL] [Abstract][Full Text] [Related]
3. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC
Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739
[TBL] [Abstract][Full Text] [Related]
4. Hepatic kinetics and magnetic resonance imaging of gadolinium-EOB-DTPA in dogs.
Benness G; Khangure M; Morris I; Warwick A; Burrows P; Vogler H; Weinmann HJ
Invest Radiol; 1996 Apr; 31(4):211-7. PubMed ID: 8721960
[TBL] [Abstract][Full Text] [Related]
5. Ytterbium- and dysprosium-EOB-DTPA. A new prototype of liver-specific contrast agents for computed tomography.
Krause W; Schuhmann-Giampieri G; Bauer M; Press WR; Muschick P
Invest Radiol; 1996 Aug; 31(8):502-11. PubMed ID: 8854197
[TBL] [Abstract][Full Text] [Related]
6. Ni-DTPA doped agarose gel--a phantom material for Gd-DTPA enhancement measurements.
Tofts PS; Shuter B; Pope JM
Magn Reson Imaging; 1993; 11(1):125-33. PubMed ID: 8423715
[TBL] [Abstract][Full Text] [Related]
7. Hepatic kinetics and magnetic resonance imaging of gadolinium ethoxybenzyl diethylenetriaminepentacetic acid (Gd-EOB-DTPA) in dogs.
Benness G; Khangure M; Morris I; Warwick A; Burrows P
Australas Radiol; 1993 Aug; 37(3):252-5. PubMed ID: 8373327
[TBL] [Abstract][Full Text] [Related]
8. Multinuclear MR characterization of a new hepatobiliary contrast agent. Preliminary results.
Vander Elst L; Maton F; Laurent S; Seghi F; Muller RN
Acta Radiol Suppl; 1997; 412():135-8. PubMed ID: 9240092
[TBL] [Abstract][Full Text] [Related]
9. Elimination of gadolinium-ethoxybenzyl-DTPA in a rat model of severely impaired liver and kidney excretory function. An experimental study in rats.
Mühler A; Heinzelmann I; Weinmann HJ
Invest Radiol; 1994 Feb; 29(2):213-6. PubMed ID: 8169100
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging.
Schuhmann-Giampieri G; Frenzel T; Schmitt-Willich H
Arzneimittelforschung; 1993 Aug; 43(8):927-31. PubMed ID: 8216456
[TBL] [Abstract][Full Text] [Related]
11. Effect of varying the molecular weight of the MR contrast agent Gd-DTPA-polylysine on blood pharmacokinetics and enhancement patterns.
Vexler VS; Clément O; Schmitt-Willich H; Brasch RC
J Magn Reson Imaging; 1994; 4(3):381-8. PubMed ID: 8061437
[TBL] [Abstract][Full Text] [Related]
12. Studies of Gd-DTPA relaxivity and proton exchange rates in tissue.
Donahue KM; Burstein D; Manning WJ; Gray ML
Magn Reson Med; 1994 Jul; 32(1):66-76. PubMed ID: 8084239
[TBL] [Abstract][Full Text] [Related]
13. High resolution NMR imaging: Gd-DTPA labeled enzyme as a probe for permeability studies in polyacrylamide gels.
Spanoghe M; Lanens D; Gorrebeeck C; Dommisse R; Lemière G; Van der Linden A; Van de Vyver F
Magn Reson Imaging; 1991; 9(4):583-7. PubMed ID: 1779730
[TBL] [Abstract][Full Text] [Related]
14. Gadolinium-containing copolymeric chelates--a new potential MR contrast agent.
Unger EC; Shen D; Wu G; Stewart L; Matsunaga TO; Trouard TP
MAGMA; 1999 Aug; 8(3):154-62. PubMed ID: 10504042
[TBL] [Abstract][Full Text] [Related]
15. Concentration of gadolinium-diethylene triamine pentaacetic acid in human kidney--study on proper time for dynamic magnetic resonance imaging of the human kidney on low and high magnetic fields.
Takeda M; Katayama Y; Tsutsui T; Komeyama T; Mizusawa T; Tanikawa T; Sato S
Tohoku J Exp Med; 1993 Oct; 171(2):119-28. PubMed ID: 8128480
[TBL] [Abstract][Full Text] [Related]
16. Functional hepatobiliary imaging with gadolinium-EOB-DTPA. A comparison of magnetic resonance imaging and 153gadolinium-EOB-DTPA scintigraphy in rats.
Schmitz SA; Mühler A; Wagner S; Wolf KJ
Invest Radiol; 1996 Mar; 31(3):154-60. PubMed ID: 8675423
[TBL] [Abstract][Full Text] [Related]
17. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA.
Vogl TJ; Kümmel S; Hammerstingl R; Schellenbeck M; Schumacher G; Balzer T; Schwarz W; Müller PK; Bechstein WO; Mack MG; Söllner O; Felix R
Radiology; 1996 Jul; 200(1):59-67. PubMed ID: 8657946
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of two new gadolinium chelates as contrast agents for MRI.
Wiegers CB; Welch MJ; Sharp TL; Brown JJ; Perman WH; Sun Y; Motekaitis RJ; Martell AE
Magn Reson Imaging; 1992; 10(6):903-11. PubMed ID: 1461088
[TBL] [Abstract][Full Text] [Related]
19. Does gadolinium-diethylene triamine pentaacetic acid enhanced MRI of kidney represent tissue concentration of contrast media in the kidney? In vivo and in vitro study.
Takeda M; Katayama Y; Tsutsui T; Komeyama T; Mizusawa T
Magn Reson Imaging; 1994; 12(3):421-7. PubMed ID: 8007771
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system.
Schuhmann-Giampieri G; Schmitt-Willich H; Press WR; Negishi C; Weinmann HJ; Speck U
Radiology; 1992 Apr; 183(1):59-64. PubMed ID: 1549695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
